Isotopia Molecular Imaging
Isotopia aspired to be the world leader and innovative company in nuclear medicine by providing meaningful medical care for patients globally.
Isotopia is a Radiopharmaceutical Company established in 2006, serving the nuclear medicine field while focusing on Theragnostic applications.
Continually up to date on new advances in nuclear therapy, Isotopia also provided 177Lu treatments for prostate cancer and neuroendocrine tumors
Since 2014, Isotopia has supplied 68Ga-PSMA to the local market, as the first company to respond to this emerging technique in prostate cancer management.
In our pipeline, a cold kit for 68-Ga-PSMA-11 synthesis, soon be ready for marketing.
As part of their long-term vision, Isotopia acquired the state-of-the-art, FDA and EU-approved Aseptic pharmaceutical plant focusing on Theranostic products.
Isotopia closed long-term contracts for the starting materials to produce 177Lu n.c.a together with long-term agreements with three different nuclear reactors. All the chain of supply is closed with rigid contracts. Today Isotopia distributes this Isotope to 30 different customers on twelve continents.
As we continue to implement Isotopia’s vision, we welcome opportunities for collaboration with companies and academic institutes to develop new markers, radiopharmaceutical production, and international sales.
www.isotopia-global.com
Brands: Lu-177 n.c.a, Lu-177 c.a, isoPROtrace-11® - PSMA Cold kit